Table 5.
Circulating tumor DNA (ctDNA) levels and percent abundance mutant DNA relative to cell free DNA (cfDNA) in participants with a confirmed cancer diagnosis within one-year of DNA sampling
| Subject | Age (years)/Gender | Number of Samples (Date of Collection) | Mutation | Copy Number | Abundance Mutant ctDNA relative to input cfDNA (%) | Pathology Result |
|---|---|---|---|---|---|---|
| 1 | 51/Male | Sample 1 (Feb. 2016) | TP53_e7a_R248W | 6.2 | 0.023 | Adenocarcinoma of the prostate, Gleason 6 (Oct. 2016); melanoma (Nov. 2016). |
| Sample 2 (July 2016) | 7.5 | 0.028 | ||||
| Sample 3 (March 2017) | 8.1 | 0.031 | Sample obtained following prostatectomy (Dec. 2016); melanoma removed locally (Dec. 2016), no other treatment. | |||
| 2 | 75/Male | Sample 1 (June 2016) | GNAS_e8a_R201H | 218.6 | 1.742 | Adenocarcinoma of the lung, stage 1 (Abdominal CT scan, Aug. 2016) |
| Sample 2 (Aug. 2016) | 629 | 3.089 | ||||
| Sample 3 (Dec. 2016) | 248.4 | 1.589 | Sample obtained following partial pneumonectomy (Oct. 2016) | |||
| Sample 4 (June 2017) | 253.2 | 1.882 | ||||
| 3 | 66/Female | Sample 1 (April 2016) | KRAS_e2a_G12D | 2.5 | 0.024 | |
| TP53_e5a_R175H | 2.9 | 0.028 | ||||
| Sample 2 (July 2016) | KRAS_e2a_G12D | 15.6 | 0.058 | Subject hospitalized Aug. 2016 and diagnosed with pancreatic cancer at workup. | ||
| TP53_e5a_R175H | 6.8 | 0.025 | Subject died Oct. 2016 three months after second sample obtained. | |||
| 4 | 71/Male | Sample 1 (June 2016) | TP53_e7a_G245D | 2.2 | 0.005 | Subject died Sep. 2016 from probable myelodysplastic syndrome. |
| TP53_e7a_R248W | 3.6 | 0.009 | ||||
| TP53_e8a_R273H | 4.0 | 0.01 |